Market OverviewTwice-yearly lipid-lowering therapies are reshaping adherence economics in the cardiovascular drugs market by reducing the burden of daily oral medication for high-risk patients. Long-acting RNA interference therapies and other extended-interval treatments can provide durable LDL cholesterol reduction with infrequent administration. The Cardiovascular Drugs Market is projected to...
English
Arabic
French
Spanish
Portuguese
Deutsch
Turkish
Dutch
Italiano
Russian
Romaian
Greek